Raia DrogasilBSP:RADL3 +3.53%91 PS Ratio is 0.69 as of Jul. 11, 2026, which is 52% below its 10-year median of 1.43. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$29.98 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 659 Healthcare Providers & Services companies, Raia Drogasil ranks better than 73.44% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Raia Drogasil's share price is R$18.77.
Raia Drogasil's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was R$27.10. Hence, Raia Drogasil's PS Ratio for today is 0.69.
The historical rank and industry rank for Raia Drogasil's PS Ratio or its related term are showing as below:
BSP:RADL3'
s PS Ratio Range Over the Past 10 Years
Min: 0.56 Med: 1.43 Max: 2.33
Current: 0.69
During the past 13 years, Raia Drogasil's highest PS Ratio was 2.33. The lowest was 0.56. And the median was 1.43.
BSP:RADL3's PS Ratio is ranked better than 73.44% of 659
companies
in the Healthcare Providers & Services industry
Industry Median: 1.48
vs BSP:RADL3: 0.69
Raia Drogasil SA has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Raia Drogasil was 18.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 15.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 18.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 17.90% per year.
During the past 13 years, Raia Drogasil's highest 3-Year average Revenue per Share Growth Rate was 36.50% per year. The lowest was 13.00% per year. And the median was 19.20% per year.
Back to Basics: PS Ratio
Raia Drogasil (BSP:RADL3) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Raia Drogasil PS Ratio Related Terms
Raia Drogasil PS Ratio Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's PS Ratio distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Raia Drogasil's Share Price of today is R$18.77. Raia Drogasil's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$27.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Raia Drogasil (BSP:RADL3) has a PS Ratio of 0.69 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Raia Drogasil and its competitors. This is 52% below median its historical median of 1.43. Over the past decade, Raia Drogasil's PS Ratio has ranged from 0.56 to 2.33. According to the industry distribution chart, Raia Drogasil ranks #175 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 26.6%.
Is Raia Drogasil's PS Ratio too high?
Raia Drogasil's current PS Ratio of 0.69 is 52% below median its 10-year median of 1.43. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 2.33. The Healthcare Providers & Services industry median PS Ratio is 1.48. Raia Drogasil's value of 0.69 is 53.4% below this industry median. Based on the distribution chart, Raia Drogasil ranks #175 out of 659 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's PS Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #175 out of 659 companies for PS Ratio. This puts Raia Drogasil in the upper half of its industry. The industry median PS Ratio is 1.48. Raia Drogasil's value of 0.69 is 53.4% below this benchmark. Historically, Raia Drogasil's own PS Ratio has ranged from 0.56 to 2.33 over the past decade. While the company's 10-year median is 1.43 vs. the industry median of 1.48, Raia Drogasil has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.48, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current PS Ratio of 0.69 is 53.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current PS Ratio is 0.69, which is 52% below median its own 10-year median of 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$29.98, compared to a current price of R$18.77 — trading 37.4% below its estimated fair value. The current PS Ratio is 0.69, which is 52% below median its 10-year median of 1.43 and 53.4% below the Healthcare Providers & Services industry median of 1.48. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current PS Ratio is 0.69 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$18.77 is trading 37.4% below its estimated GF Value™ of R$29.98.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
PS Ratio: 0.69 (52% below median its 10-year median of 1.43)
GF Value™: R$29.98 vs. price of R$18.77 (37.4% below fair value)
Industry Position: 53.4% below the Healthcare Providers & Services median (#175 of 659)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
